From: Risk and prognostic factors of breast cancer with liver metastases
Variable | Patients, No. % |
---|---|
Patients (n = 1728) | |
Age at diagnosis, y | |
 21–40 | 288 (16.7%) |
 41–60 | 1143 (66.1%) |
  > 60 | 297 (17.2%) |
Histology | |
 Infiltrating duct carcinoma | 1396 (80.8%) |
 Lobular carcinoma | 31 (1.8%) |
 Other | 301 (17.4%) |
De novo metastatic diseases | |
 No | 1526 (88.3%) |
 Yes | 202 (11.7%) |
Surgery of primary site | |
 No | 219 (12.7%) |
 Yes | 1509 (87.3%) |
Prior Chemotherapy | |
 No | 226 (13.1%) |
 Yes | 1502 (86.9%) |
Prior Radiotherapy | |
 No | 848 (49.1%) |
 Yes | 785 (45.4%) |
 Unknown | 95 (5.5%) |
Recurrent sequence | |
 First liver metastases | 1087 (62.9%) |
 Subsequent liver metastases | 641 (37.1%) |
Extrahepatic metastatic sites to lung, brain, bone and lymph nodes, No | |
 0 | 561 (32.5%) |
 1 | 534 (30.9%) |
 2 | 382 (22.1%) |
 3 | 223 (12.9%) |
 All 4 | 28 (1.6%) |
Subtype | |
 HR+/HER2− | 767 (44.3%) |
 HR+/HER2+ | 305 (17.7%) |
 HR−/HER2+ | 321 (18.6%) |
 Triple-negative | 270 (15.6%) |
 Unknown | 65 (3.8%) |